Introduction: Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis play a significant
role in the adjuvant and metastatic treatment of non-small cell lung cancer (NSCLC). PD-L1 …

Background Anti-PD-(L) 1 agents play an important role in the management of NSCLC. PD-
L1 analysis by immunohistochemistry is an important biomarker but displays temporospatial …

Background Advances in the management of early stage NSCLC include the introduction of
PD-1/PD-L1 checkpoint inhibitors. PD-L1 is an important biomarker but its role in early …

Abstract Purpose Anti-PD-1/PD-L1 blockade can restore tumour-specific T-cell immunity and
is an emerging therapy in non-small-cell lung cancer (NSCLC). We investigated the …

Purpose Eliciting antitumor T-cell response by targeting the PD-1/PD-L1 axis with
checkpoint inhibitors has emerged as a novel therapeutic strategy in non-small cell lung …

241943 Introduction: Lung cancer is one of the most common cancers, causing significant
morbidity and mortality. F-18 FDG PET/CT has a proven value in diagnosing and staging …

Background Programmed death-ligand 1 (PD-L1) expression is a predictive biomarker for
immunotherapy in non-small cell lung cancer (NSCLC). PD-L1 and glucose transporter 1 …

Background Immunotherapy targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-
L1) has shown promising results in non-small cell lung cancer (NSCLC) patients. Exploring …

Background This study aimed to determine the relationship of programmed death-ligand 1
(PD-L1) expression and standardized uptake values in fluorodeoxyglucose–positron …

Objective The aim of this study is to evaluate correlation between Programmed cell death
ligand 1 (PD-L1) mutation status with metabolic parameters derived from 18-F Fluoro-2 …